COMP <GO>
ENTA vs PRLD // FREE CASH FLOW YIELD
Enanta Pharmaceuticals Inc. (NASDAQ) VS. Prelude Therapeutics Incorporated (NASDAQ) • 15-METRIC TALLY: ENTA 1
— PRLD 4
▲ FREE CASH FLOW YIELD LEADER: ENTA
LAST: $11.15 (-3.46%) • MKT CAP: $324.7M
fcf-yield
-9.91%
LAST: $4.10 (-0.97%) • MKT CAP: $327.2M
fcf-yield
-17.23%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTA VS. PRLD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENTA | PRLD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -9.91% | -17.23% | +7.32 | ENTA | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -3.40% | 73.40% | -76.80 | PRLD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | PRLD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.6 | 49.1 | -12.45 | PRLD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $324.7M | $327.2M | -$2.4M | PRLD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENTA REV | PRLD REV | ENTA GROSS % | PRLD GROSS % | ENTA FCF | PRLD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.3M | $12.1M | — | — | -$32.2M | -$56.4M |
| FY 2024 | $67.6M | $7.0M | — | — | -$96.7M | -$103.7M |
| FY 2023 | $79.2M | $0 | — | — | -$103.2M | -$107.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTA // BETA —
PRLD // BETA —